Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2025)

Treace Medical Concepts' Cash from Financing Activities history spans 6 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 5215.38% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $2.1 million, up 1198.12%, while the annual FY2025 figure was $2.1 million, 1198.12% up from the prior year.
  • Cash from Financing Activities reached $1.4 million in Q4 2025 per TMCI's latest filing, up from -$10000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $107.9 million in Q1 2023 to a low of -$1.2 million in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $12.0 million, with a median of $304000.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: crashed 3793.94% in 2021, then skyrocketed 7762.9% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.0 million in 2021, then tumbled by 71.05% to $297000.0 in 2022, then plummeted by 44.44% to $165000.0 in 2023, then tumbled by 84.24% to $26000.0 in 2024, then skyrocketed by 5215.38% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Cash from Financing Activities are $1.4 million (Q4 2025), -$10000.0 (Q3 2025), and $987000.0 (Q2 2025).